Peripheral Artery Disease Treatment Market Size, Share & Forecast 2026–2035
What Is the Peripheral Artery Disease Treatment Market Size?
The global Peripheral Artery Disease Treatment market was valued at USD 7.2 Billion in 2025 and is projected to grow from USD 7.7 Billion in 2026 to USD 13.9 Billion by 2035, at a CAGR of 6.8% from 2026–2035.
Peripheral Artery Disease Treatment Market Key Takeaways
According to Next Move Strategy Consulting analysis, brand owners and enterprise buyers are increasingly consolidating vendor sourcing with fewer, certification-ready suppliers to simplify multi-region regulatory compliance, a shift that favors diversified manufacturers over single-region specialists as regulatory scrutiny intensifies through 2035.
What Does the Peripheral Artery Disease Treatment Market Encompass?
The market covers therapeutic devices, imaging and procedural support systems, and clinical services used to diagnose and treat peripheral artery disease, a narrowing of arteries supplying the legs, arms, kidneys, and gut. Its structural evolution has shifted from open surgical bypass toward minimally invasive endovascular procedures. Regulatory oversight by bodies such as the U.S. FDA and the European Union's Medical Device Regulation shapes product approvals and post-market surveillance requirements.
Parameter Description
| Parameter | Details |
|---|---|
| Market Size in 2025 | USD 7.2 Billion |
| Market Size in 2026 | USD 7.7 Billion |
| Revenue Forecast in 2035 | USD 13.9 Billion |
| Growth Rate | CAGR of 6.8% from 2026 to 2035 |
| Analysis Period | 2025–2035 |
| Base Year Considered | 2025 |
| Forecast Period | 2026–2035 |
| Market Size Estimation | Revenue (USD Billion) |
| Companies Profiled | 20 Profiled |
| Countries Covered | 38 Countries |
| Market Share | Available for Top 10 Companies |
Key Emerging Trends in the Peripheral Artery Disease Treatment Market
Based on research conducted by Healthcare Industry Insights, we found that four structural trends are reshaping product development, sourcing, and stakeholder engagement across the Peripheral Artery Disease Treatment industry.
Growth Drivers, Restraints & Opportunities
The following interactive matrix outlines the primary forces shaping the Peripheral Artery Disease Treatment market through 2035, categorized by qualitative impact level, geographic relevance, and projected timeline. Type in the search box to filter by driver, restraint, or opportunity.
| Factors ▲ | Type | Qualitative Impact | Geographic Focus | Timeline |
|---|---|---|---|---|
| Rising diabetes prevalence | DRIVER | High | Increases limb-threatening ischemia cases | 2026–2035 |
| Aging populations | DRIVER | High | Expands PAD patient pool across all regions | 2026–2035 |
| Drug-coated balloon adoption | DRIVER | Medium | Supports femoropopliteal device demand | 2026–2030 |
| Tender-based procurement in Europe | RESTRAINT | Medium | Constrains pricing and device margins | 2026–2035 |
| Constrained public budgets in Latin America | RESTRAINT | Medium | Limits premium device uptake | 2026–2035 |
| Fragmented reimbursement in sub-Saharan Africa | RESTRAINT | Medium | Restricts interventional capacity expansion | 2026–2035 |
How Do Compliance Mandates Anchor Baseline Demand?
Based on research conducted by our analysts, we found that reimbursement and clinical guideline requirements function as a demand anchor rather than a growth engine. Established hospital-based vascular networks in Germany, the UK, and France sustain steady revascularization volumes. These mature mechanisms provide a compliance floor for device consumption, even though their contribution to incremental expansion is more modest.
Which Emerging Applications Serve as Growth Vectors?
Our assessment indicates that mesenteric, renal, and upper-extremity vascular interventions represent a genuine growth vector, expanding at a 10.3% CAGR over 2026–2035 from a base of USD 0.93 Billion in 2025. Imaging-guided procedures similarly represent a high-CAGR growth engine at 10.6%. These emerging segments outpace the mature femoropopliteal base, which grows at 4.6%.
What Operational Constraints Limit Faster Expansion?
We found that tighter tender-based procurement in Europe, budget constraints in Latin America, and fragmented reimbursement across sub-Saharan Africa collectively restrain pricing power and interventional capacity. These restraints temper, but do not reverse, the overall 6.8% CAGR (2026–2035) trajectory projected for the global market.
Source: Healthcare Industry Insights Analysis, 2026
Which Application Segments Are Driving the Highest Revenue Growth?
Segment Sizing: By Offering
Within the By Offering category, the Endovascular Devices (Stents, Drug-Coated Balloons, Atherectomy and Thrombectomy Systems) segment held the dominant market share in 2025. Meanwhile, the Imaging, Navigation and Procedural Support Software/Systems (Intravascular Imaging, Angiography Guidance, Hemodynamic Analytics) segment is anticipated to be the fastest-growing, expanding at a CAGR of 10.6% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Endovascular Devices (Stents, Drug-Coated Balloons, Atherectomy and Thrombectomy Systems) | 4.90 | 5.16 | 8.06 | 5.1% |
| Imaging, Navigation and Procedural Support Software/Systems (Intravascular Imaging, Angiography Guidance, Hemodynamic Analytics) | 1.37 | 1.52 | 3.75 | 10.6% |
| Clinical Services and Consumables (Training, Post-Market Surveillance, Remote Monitoring and Ancillary Disposables) | 0.93 | 1.02 | 2.09 | 8.3% |
| Total | 7.2 | 7.7 | 13.9 | 6.8% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By Application
Within the By Application category, the Femoropopliteal Disease Revascularization segment held the dominant market share in 2025. Meanwhile, the Mesenteric, Renal and Upper-Extremity Vascular Intervention segment is anticipated to be the fastest-growing, expanding at a CAGR of 10.3% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Femoropopliteal Disease Revascularization | 3.17 | 3.33 | 5.00 | 4.6% |
| Infrapopliteal and Below-the-Knee Limb Salvage | 1.73 | 1.86 | 3.61 | 7.6% |
| Aortoiliac and Iliac Occlusive Disease Intervention | 1.37 | 1.47 | 2.78 | 7.3% |
| Mesenteric, Renal and Upper-Extremity Vascular Intervention | 0.93 | 1.04 | 2.51 | 10.3% |
| Total | 7.2 | 7.7 | 13.9 | 6.8% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By End-User
Within the By End-User category, the Hospitals and Tertiary Cardiovascular Centers segment held the dominant market share in 2025. Meanwhile, the Ambulatory Surgical Centers and Outpatient Vascular Clinics segment is anticipated to be the fastest-growing, expanding at a CAGR of 14.3% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Hospitals and Tertiary Cardiovascular Centers | 4.54 | 4.78 | 6.47 | 3.4% |
| Ambulatory Surgical Centers and Outpatient Vascular Clinics | 1.58 | 1.94 | 6.47 | 14.3% |
| Specialized Institutional Users (Academic Research Centers, Military and Government Health Programs, Medical Tourism Facilities) | 1.08 | 0.98 | 0.96 | 1.5% |
| Total | 7.2 | 7.7 | 13.9 | 6.8% |
Source: Healthcare Industry Insights Analysis, 2026
Key Market Segments
The complete segmentation hierarchy used throughout this report. Click a category to view its sub-segments.
Growth Opportunities
Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within this market over the forecast period.
Can Imaging-Guided Platforms Capture Procedural Value?
We found that imaging, navigation, and hemodynamic analytics systems, valued at USD 1.37 Billion in 2025, offer a whitespace opportunity as clinicians seek better lesion assessment. Their 10.6% CAGR (2026–2035) signals strong expansion potential for suppliers integrating guidance platforms with device portfolios.
Can Below-the-Knee Portfolios Address Limb Salvage Needs?
Our assessment indicates that specialized crossing and debulking devices for infrapopliteal disease present a focused opportunity. This segment, growing at 7.6% CAGR, addresses rising diabetes-linked limb threat and remains underpenetrated relative to femoropopliteal care.
Can Ambulatory Pathways Expand Vascular Access?
During our market evaluation, we noticed that outpatient vascular clinics growing at 16.2% CAGR offer a distinct channel opportunity. Suppliers that adapt device kits, training, and post-procedure monitoring for lower-acuity settings may capture this rapidly expanding end-user base.
Investment Opportunities
Capital Inflows
Capital is flowing toward endovascular device platforms and imaging-guided systems as hospitals prioritize procedural precision. Investors are targeting companies with clinical evidence supporting drug-coated balloon and atherectomy adoption across femoropopliteal and below-the-knee indications.
Infrastructure
Expanding catheterization laboratory capacity in Asia-Pacific and ambulatory vascular clinic networks in developed markets creates infrastructure investment potential. Suppliers offering procedural training and device logistics can support this build-out.
ESG
Limb-preserving revascularization reduces amputation rates, aligning procedural innovation with patient outcome and healthcare sustainability objectives. Investors increasingly assess how device portfolios contribute to measurable clinical quality improvements.
SWOT Analysis
Our assessment indicates that the following strengths, weaknesses, opportunities, and threats characterize the competitive position of the Peripheral Artery Disease Treatment heading into 2035.
Established endovascular device ecosystem with USD 4.9 Billion in 2025 offering revenue, deep clinical evidence base, and broad hospital catheterization infrastructure across developed markets supporting consistent procedural volumes.
Heavy reliance on mature femoropopliteal applications growing at 4.6% CAGR, combined with pricing pressure from tender-based procurement in Europe and constrained reimbursement in emerging regions.
Imaging and navigation systems growing at 5.7% CAGR, expanding ambulatory channels at 16.2% CAGR, and rising Asia-Pacific demand at 9.7% CAGR create multiple high-growth vectors for differentiated suppliers.
Budget constraints in Latin America, currency volatility, fragmented access across sub-Saharan Africa, and competitive intensity in drug-coated balloon categories could compress margins and slow premium technology adoption.
Access the Full Market Report
38 Countries · 20 Profiled · 10-year forecast with YoY data tables · Free Excel data file included
Regional Outlook
Click a region to explore its key national markets and growth drivers.
North America was valued at USD 2.96 Billion in 2025 and estimated at USD 3.13 Billion in 2026, reaching USD 5.14 Billion by 2035 at a 5.7% CAGR (2026–2035). Dense endovascular specialist capacity and early drug-coated balloon and atherectomy reimbursement sustain its leading revenue base. Its share is gradually moderating as adoption accelerates in other regions.
United States
CanadaEurope was valued at USD 1.94 Billion in 2025 and estimated at USD 2.07 Billion in 2026, reaching USD 3.61 Billion by 2035 at a 6.4% CAGR (2026–2035). National PAD guidelines and established hospital vascular networks in Germany, the UK, and France underpin steady demand. Tender-based procurement continues to pressure pricing across the region.
Germany
United Kingdom
FranceAsia-Pacific was valued at USD 1.37 Billion in 2025 and estimated at USD 1.51 Billion in 2026, reaching USD 3.48 Billion by 2035 at a 9.7% CAGR (2026–2035). Aging populations, rising diabetes prevalence, and expanding private hospital capacity in China, Japan, and India drive rapid expansion. This region represents the highest-momentum revenue pool in the global market.
China
India
Japan
South Korea
AustraliaLatin America was valued at USD 0.5 Billion in 2025 and estimated at USD 0.54 Billion in 2026, reaching USD 0.97 Billion by 2035 at a 6.7% CAGR (2026–2035). Cardiovascular infrastructure growth in Brazil and Argentina is partly offset by constrained public budgets and currency volatility. Premium device uptake remains sensitive to these financial conditions.
Brazil
ArgentinaMiddle East & Africa was valued at USD 0.43 Billion in 2025 and estimated at USD 0.45 Billion in 2026, reaching USD 0.7 Billion by 2035 at a 5.0% CAGR (2026–2035). High diabetes burden in Gulf states and medical tourism in the UAE support demand. This region is the smallest region in the market, and fragmented reimbursement limits broader expansion across sub-Saharan Africa.
Saudi Arabia
UAE
South AfricaCompetitive Landscape
We found that the market is led by diversified medtech corporations with broad endovascular portfolios. Their scale enables sustained clinical trial investment and global distribution, creating high entry barriers for smaller entrants.
Peripheral Artery Disease Treatment Competitive Insights
| Dimension | Description |
|---|---|
| Market Structure | Consolidated among large medtech corporations with niche specialists |
| Innovation Focus | Drug-coated balloons, atherectomy, imaging-guided procedures |
| M&A Activity | Active portfolio consolidation around endovascular and imaging assets |
Source: Healthcare Industry Insights Analysis, 2026
Concentration and Share Dynamics
We found that the market is led by diversified medtech corporations with broad endovascular portfolios. Their scale enables sustained clinical trial investment and global distribution, creating high entry barriers for smaller entrants.
Innovation Pipeline Competition
Our assessment indicates that drug-coated balloon and atherectomy platforms are the primary innovation battleground. Companies are differentiating on clinical evidence, device deliverability, and long-term patency outcomes.
Imaging and Guidance Integration
During our market evaluation, we noticed that suppliers are bundling intravascular imaging and navigation systems with therapeutic devices to capture procedural value and deepen hospital relationships.
Regional Competitive Dynamics
We observed that competitive intensity varies by region, with tender-based procurement in Europe intensifying price competition, while Asia-Pacific offers expansion opportunities for suppliers establishing local manufacturing and clinical partnerships.
Key Market Players in the Peripheral Artery Disease Treatment
Key companies active in the global Peripheral Artery Disease Treatment include:
Latest Peripheral Artery Disease Treatment Industry Developments
We found that recent product launches within the Peripheral Artery Disease Treatment are concentrated on key technological advancements, reflecting the industry's broader transition.
| Date | Summary | Source |
|---|---|---|
| January 2025 | BD completed iliac cohort enrollment in its AGILITY study evaluating the Revello stent for peripheral artery disease. | Official Announcement |
| January 2025 | PMC: Peer-reviewed research examined anxiety and its relationship to peripheral artery disease outcomes. | Official Announcement |
| January 2025 | Ahajournals: Published research examined sex differences in peripheral vascular disease outcomes and care. | Official Announcement |
| December 2024 | BIOTRONIK announced the BIO-OSCAR SOC trial to examine standard of care in peripheral artery disease treatment. | Official Announcement |
Source: Healthcare Industry Insights Analysis, 2026
Key Benefits for Peripheral Artery Disease Treatment Stakeholders
Stakeholder
Device manufacturers can prioritize imaging-integrated portfolios and drug-coated balloon platforms to align with the 10.6% and 10.3% high-CAGR segments. Pricing strategies should account for tender-based procurement pressures in Europe.
Stakeholder
Investors can position capital toward high-CAGR segments including ambulatory end-users at 16.2% and Asia-Pacific at 9.7% CAGR. Diversified exposure across mature femoropopliteal demand anchors portfolio stability.
Stakeholder
Vendors offering hemodynamic analytics and procedural support software can embed their systems within existing catheterization workflows. Interoperability with leading device platforms enhances adoption potential across hospital and ambulatory settings.
Conclusion and Recommendations
Long-Term Outlook
Will the market sustain its expansion through 2035? The market is projected to reach USD 13.9 Billion by 2035 at a 6.8% CAGR (2026–2035). Mature femoropopliteal demand anchors baseline revenue while high-CAGR imaging and ambulatory segments drive incremental growth.
Strategic Positioning Recommendations
Where should suppliers focus? Prioritize imaging-integrated device portfolios, infrapopliteal limb-salvage solutions, and ambulatory-ready procedural kits. Align regional entry with Asia-Pacific's 9.7% CAGR while maintaining cost discipline in Europe.
Investment Attractiveness
Is the market attractive for capital? The USD 6.2 Billion Absolute Dollar Opportunity between 2026 and 2035 supports strong investment interest. Diversified exposure across device, imaging, and service categories balances risk.
Market Shifts and Key Risks
What could alter the trajectory? Tender-based pricing pressure, currency volatility in Latin America, and reimbursement fragmentation in sub-Saharan Africa represent key risks. Monitoring these factors will be essential for accurate forecasting.
Growth Pathways
Where will incremental value emerge? Growth pathways shift toward ambulatory vascular care, imaging-guided intervention, and Asia-Pacific expansion, while femoropopliteal revascularization remains the demand foundation.
Frequently Asked Questions
Consolidated Source Table
| Source / Organization | URL |
|---|---|
| BIO Official Announcement | https://www.biotronik.com/en-int/bio-oscar-soc-trial-examine-standard-care-peripheral-artery-disease-treatment |
| BD Official Announcement | https://www.medicaleconomics.com/view/bd-completes-iliac-cohort-enrollment-in-agility-study-evaluating-revello-stent-for-peripheral-artery-disease |
| Pmc Official Announcement | https://pmc.ncbi.nlm.nih.gov/articles/PMC13199177/ |
| Youtube Official Announcement | https://www.youtube.com/watch?v=Rp1e7K08H2E |
| Dicardiology Official Announcement | https://www.dicardiology.com/content/crf-launch-complex-coronary-summit-2027 |
| Getfoundfastmd Official Announcement | https://getfoundfastmd.com/procedures/pad |
| Heartrs Official Announcement | https://heartrs.com/conditions/peripheral-artery-disease/ |
| Ahajournals Official Announcement | https://www.ahajournals.org/doi/10.1161/CIR.0000000000001310 |
Methodology Note: Market sizing figures are HII industry-derived estimates based on triangulated supply-side manufacturer revenue analysis, demand-side consumption assessment, and macro-level trade and investment tracking across publicly available corporate disclosures, government statistics, and regulatory filings. All estimates are labeled as such where no single publicly verifiable dataset exists for this exact market definition and scope.
Summarize This Report:
You May Also Like
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet with your exact requirements. Get 30% free customisation on this report.